News

€12m to develop a Crohn’s therapy
Enlarge image

BusinessFrance

€12m to develop a Crohn’s therapy

27.11.2012 - French TxCell closes a third financing round. With €12.4m, the company will bring its T cell-based immunotherapy for Crohn’s disease into Phase III.

TxCell SA is a biotechnology company from Valbonne specialising in T cell-based immunotherapies for the treatment of severe chronic inflammatory diseases. On 26 November, it announced the successful closure of a third financing round for €12.4m. The money largely comes from the InnoBio fund. Managed by CDC Enterprises, the fund accounts for €6m. The remaining amount has been provided by TxCell’s existing shareholders Auriga Partners and Seventure Partners, two venture capital firms firmly rooted in France. Both VCs have a strong background in biotechnology. Auriga also financed lab equipment specialist Cytoo SA from Grenoble, Seventure a biofuel plant in Toulouse .

These additional financial resources will enable TxCell to pursue the development of its lead product candidate, Ovasave®. The antigen-specific Treg cell-based immunotherapy is for the treatment of Crohn’s disease in patients who are refractory to current treatments. Laurent Arthaud, Deputy CEO at CDC Entreprises said: “We are impressed by the innovative therapeutic approach and the encouraging positive clinical data obtained so far by TxCell. The company has a strong and experienced management team in place, and this capital injection will provide the necessary resources to confirm the clinical findings obtained so far and reach the next important development milestone.” To date, TxCell has completed a first in man Phase I/II clinical study that proved tolerability and efficacy of Ovasave®. 

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/eur12m-to-develop-a-crohns-therapy.html

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

Events

All Events

Current issue

All issues

Product of the week

Products